GV1001 not checked

Samsung Pharmaceutical Co., Ltd. · GemVax & Kael · Tertomotide 1.68mg · Tertomotide 0.84mg

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
1 active
8 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Moderate to Severe Alzheimer's Disease
Main trialPhase 3
“The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).”In the company’s words, NCT05303701 on ClinicalTrials.gov
Other names
Tertomotide 1.68mg · Tertomotide 0.84mg · Tertomotide

Other drugs for Moderate to Severe Alzheimer's Disease

All 90 drugs for Moderate to Severe Alzheimer's Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Jan 2028 GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Phase 3Completed 17 Mar 2022 Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Phase 2Completed Oct 2016 A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
Phase 2Withdrawn 31 Aug 2021 GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
Phase 2Completed 11 Oct 2024 GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Phase 2Completed 3 Apr 2025 GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Phase 2Completed 1 Sep 2025 Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
Phase 1Completed 25 Aug 2025 Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow GV1001

Following is part of Solo: you see every change to GV1001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in